View Author
patient lymphocytes cancer t cells t-cell transduction response therapy t lymphocytes blood level number study receptor culture treatment antibody production activation antigen expression tumor rtvsup cytokine assay figure transduced protocol result vector autologou range lamer donor sample transfer activity clone serum control il -15 immunol cycle -12 lymphocyte protein carcinoma cd 4 þ marker month melanoma infusion transgene group metastatic table target effect car t cells immunogene therapy gene transduction erasmus mc panel medium disease cell carcinoma count chain retronectin cytometry chimeric expansion transplantation method cytolysis flow cytometry signi ficantly -15 efficiency trial
10 Most Recent Publications
|
Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells
(Article)
Lamers, C.H.J. Elzakker, P.M.M.L. van Steenbergen, S.L.C. van Luider, B.A. Groot, C. Krimpen, B.A. van Vulto, A.G. Sleijfer, S. Debets, J.E.M.A. Gratama, J-W. |
2013-05-01
|
|
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
(Article)
Lamers, C.H.J. Willemsen, R.A. Elzakker, P.M.M.L. van Steenbergen-Langeveld, S. van Broertjes, M. Oosterwijk-Wakka, J. Oosterwijk, E. Sleijfer, S. Debets, J.E.M.A. Gratama, J-W. |
2011-01-06
|
|
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials
(Article)
Davis, J.L. Theoret, M.R. Zheng, Z. Lamers, C.H.J. Rosenberg, S.A. Morgan, R.A. |
2010-12-01
|
|
Levels of circulating endothelial cells in normotensive and severe preeclamptic pregnancies
(Article)
Strijbos, M.H. Snijder, C.A. Kraan, J. Lamers, C.H.J. Gratama, J-W. Duvekot, J.J. |
2010-11-01
|
|
Levels of circulating endothelial cells in normotensive and severe preeclamptic pregnancies
(Article)
Strijbos, M.H. Snijder, C.A. Kraan, J. Lamers, C.H.J. Gratama, J-W. Duvekot, J.J. |
2010-11-01
|
|
mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells
(Article)
Strijbos, M.H. Krimpen, B.A. van Debets, J.E.M.A. Kraan, J. Sleijfer, S. Gratama, J-W. Lamers, C.H.J. |
2010-08-01
|
|
T cell receptor (TCR) gene therapy to treat melanoma: Lessons from clinical and preclinical studies
(Article)
Coccoris, M. Straetemans, G.C.M. Govers, C. Lamers, C.H.J. Sleijfer, S. Debets, J.E.M.A. |
2010-04-01
|
|
TCR gene-engineered T cell: Limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity
(Article)
Pouw, N.M.C. Treffers-Westerlaken, E. Mondino, A. Lamers, C.H.J. Debets, J.E.M.A. |
2010-03-18
|
|
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours
(Article)
Kitzen, J.J.E.M. Jonge, M.J.A. de Lamers, C.H.J. Eskens, F.A.L.M. Biessen, D. van der Doorn, L. van Steeg, J. ter Brandely, M. Puozzo, C. Verweij, J. |
2009-07-01
|
|
Quantification of circulating endothelial cells by flow cytometry
(Article)
Strijbos, M.H. Kraan, J. Lamers, C.H.J. Sleijfer, S. Gratama, J-W. |
2009-05-15
|
